Magnetic Levitation Lifts Impurities from Pharmaceuticals

Separating therapeutic molecules from nonhelpful "twins" is tough, but a new magnetic method that can pull them apart may be the answer

Join Our Community of Science Lovers!

A team in the US has shown that enantiopure and racemic crystals can be separated by magnetic levitation.

The isolation of pure enantiomers is of particular importance in the pharmaceutical industry, where one enantiomer is typically responsible for the therapeutic effects of a drug, while the other may be inactive or even toxic. One alternative to the often used solution-based separation techniques such as high-performance liquid chromatography (HPLC) is to purify the desired enantiomer from a mixture of crystals of enantiomerically pure and racemic compound.

As enantiopure and racemic crystals generally have different densities due to distinct packing arrangements of the molecules, they can be levitated in a paramagnetic solution to different heights by the balance of magnetic and gravitational forces and then separated.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Using four sequential magnetic levitation (MagLev) separations, a team led by Allan Myerson at the Massachusetts Institute of Technology purified a 1:1 mixture of S- and RS-ibuprofen to 99.2% ee.

‘Chiral resolution, especially during drug discovery, requires tedious method development by an experienced scientist to achieve efficient separation,’ says Syed Rizvi, a chiral separations and pharmaceutical analysis expert at Nova Southeastern University in the US. ‘The MagLev technique however is quite simple, inexpensive and has great potential to become a routine method for chiral separation.’

Despite its simplicity, the use of MagLev on a large scale presents a number of challenges. ‘As it requires that the racemic crystal forms reliably, does not stick to enantiomerically pure crystals, and has a different density, it is more likely to be used in an analytical laboratory setting engaged in preclinical studies of a compound,’ says Myerson. The need for an equilibration time for the drug crystals to settle as well as the choice of paramagnetic medium also need to be considered.

The team are currently working to apply MagLev to the purification of other chiral compounds, and hope to extend their technique to the separation of cocrystals.

This article is reproduced with permission from Chemistry World. The article was first published on June 18, 2014.

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe